Cargando…

Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population

BACKGROUND: The cause of heart failure with preserved ejection fraction (HFpEF) is poorly understood, and specific therapies are lacking. Previous studies suggested that inflammation plays a role in the development of HFpEF. Herein, we aimed to investigate in community‐dwelling individuals whether a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Yook Chin, Kieneker, Lyanne M., van Hassel, Gaston, Binnenmars, S. Heleen, Nolte, Ilja M., van Zanden, Jelmer J., van der Meer, Peter, Navis, Gerjan, Voors, Adriaan A., Bakker, Stephan J. L., De Borst, Martin H., Eisenga, Michele F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483531/
https://www.ncbi.nlm.nih.gov/pubmed/33998283
http://dx.doi.org/10.1161/JAHA.120.018549
_version_ 1784577152101908480
author Chia, Yook Chin
Kieneker, Lyanne M.
van Hassel, Gaston
Binnenmars, S. Heleen
Nolte, Ilja M.
van Zanden, Jelmer J.
van der Meer, Peter
Navis, Gerjan
Voors, Adriaan A.
Bakker, Stephan J. L.
De Borst, Martin H.
Eisenga, Michele F.
author_facet Chia, Yook Chin
Kieneker, Lyanne M.
van Hassel, Gaston
Binnenmars, S. Heleen
Nolte, Ilja M.
van Zanden, Jelmer J.
van der Meer, Peter
Navis, Gerjan
Voors, Adriaan A.
Bakker, Stephan J. L.
De Borst, Martin H.
Eisenga, Michele F.
author_sort Chia, Yook Chin
collection PubMed
description BACKGROUND: The cause of heart failure with preserved ejection fraction (HFpEF) is poorly understood, and specific therapies are lacking. Previous studies suggested that inflammation plays a role in the development of HFpEF. Herein, we aimed to investigate in community‐dwelling individuals whether a higher plasma interleukin 6 (IL‐6) level is associated with an increased risk of developing new‐onset heart failure (HF) over time, and specifically HFpEF. METHODS AND RESULTS: We performed a case‐cohort study based on the PREVEND (Prevention of Renal and Vascular End‐Stage Disease) study, a prospective general population‐based cohort study. We included 961 participants, comprising 200 participants who developed HF and a random group of 761 controls. HF with reduced ejection fraction or HFpEF was defined on the basis of the left ventricular ejection fraction of ≤40% or >40%, respectively. In Cox proportional hazard regression analyses, IL‐6 levels were statistically significantly associated with the development of HF (hazard ratio [HR], 1.28; 95% CI, 1.02–1.61; P=0.03) after adjustment for key risk factors. Specifically, IL‐6 levels were significantly associated with the development of HFpEF (HR, 1.59; 95% CI, 1.16–2.19; P=0.004), whereas the association with HF with reduced ejection fraction was nonsignificant (HR, 1.05; 95% CI, 0.75–1.47; P=0.77). In sensitivity analyses, defining HFpEF as left ventricular ejection fraction ≥50%, IL‐6 levels were also significantly associated with the development of HFpEF (HR, 1.47; 95% CI, 1.04–2.06; P=0.03) after adjustment for key risk factors. CONCLUSIONS: IL‐6 is associated with new‐onset HFpEF in community‐dwelling individuals, independent of potential confounders. Our findings warrant further research to investigate whether IL‐6 might be a novel treatment target to prevent HFpEF.
format Online
Article
Text
id pubmed-8483531
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84835312021-10-06 Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population Chia, Yook Chin Kieneker, Lyanne M. van Hassel, Gaston Binnenmars, S. Heleen Nolte, Ilja M. van Zanden, Jelmer J. van der Meer, Peter Navis, Gerjan Voors, Adriaan A. Bakker, Stephan J. L. De Borst, Martin H. Eisenga, Michele F. J Am Heart Assoc Original Research BACKGROUND: The cause of heart failure with preserved ejection fraction (HFpEF) is poorly understood, and specific therapies are lacking. Previous studies suggested that inflammation plays a role in the development of HFpEF. Herein, we aimed to investigate in community‐dwelling individuals whether a higher plasma interleukin 6 (IL‐6) level is associated with an increased risk of developing new‐onset heart failure (HF) over time, and specifically HFpEF. METHODS AND RESULTS: We performed a case‐cohort study based on the PREVEND (Prevention of Renal and Vascular End‐Stage Disease) study, a prospective general population‐based cohort study. We included 961 participants, comprising 200 participants who developed HF and a random group of 761 controls. HF with reduced ejection fraction or HFpEF was defined on the basis of the left ventricular ejection fraction of ≤40% or >40%, respectively. In Cox proportional hazard regression analyses, IL‐6 levels were statistically significantly associated with the development of HF (hazard ratio [HR], 1.28; 95% CI, 1.02–1.61; P=0.03) after adjustment for key risk factors. Specifically, IL‐6 levels were significantly associated with the development of HFpEF (HR, 1.59; 95% CI, 1.16–2.19; P=0.004), whereas the association with HF with reduced ejection fraction was nonsignificant (HR, 1.05; 95% CI, 0.75–1.47; P=0.77). In sensitivity analyses, defining HFpEF as left ventricular ejection fraction ≥50%, IL‐6 levels were also significantly associated with the development of HFpEF (HR, 1.47; 95% CI, 1.04–2.06; P=0.03) after adjustment for key risk factors. CONCLUSIONS: IL‐6 is associated with new‐onset HFpEF in community‐dwelling individuals, independent of potential confounders. Our findings warrant further research to investigate whether IL‐6 might be a novel treatment target to prevent HFpEF. John Wiley and Sons Inc. 2021-05-17 /pmc/articles/PMC8483531/ /pubmed/33998283 http://dx.doi.org/10.1161/JAHA.120.018549 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Chia, Yook Chin
Kieneker, Lyanne M.
van Hassel, Gaston
Binnenmars, S. Heleen
Nolte, Ilja M.
van Zanden, Jelmer J.
van der Meer, Peter
Navis, Gerjan
Voors, Adriaan A.
Bakker, Stephan J. L.
De Borst, Martin H.
Eisenga, Michele F.
Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
title Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
title_full Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
title_fullStr Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
title_full_unstemmed Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
title_short Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
title_sort interleukin 6 and development of heart failure with preserved ejection fraction in the general population
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483531/
https://www.ncbi.nlm.nih.gov/pubmed/33998283
http://dx.doi.org/10.1161/JAHA.120.018549
work_keys_str_mv AT chiayookchin interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT kienekerlyannem interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT vanhasselgaston interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT binnenmarssheleen interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT nolteiljam interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT vanzandenjelmerj interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT vandermeerpeter interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT navisgerjan interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT voorsadriaana interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT bakkerstephanjl interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT deborstmartinh interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation
AT eisengamichelef interleukin6anddevelopmentofheartfailurewithpreservedejectionfractioninthegeneralpopulation